Final Takeaways From the Panelists

February 26, 2025

Ryan Haumschild, PharmD, MS, MBA
Amy McMichael, MD

Opinion

Video

Panelists discuss their final thoughts on the evolving landscape of alopecia areata (AA) treatment, summarizing key takeaways from the discussion and reflecting on future directions for patient care and therapy advancements.

EP: 1.Discussing the Pathophysiology of Alopecia Areata

EP: 2.Epidemiology Associated With Alopecia Areata

EP: 3.Common Comorbidities Associated With Alopecia Areata

EP: 4.Hallmark Symptoms Seen With Alopecia Areata

EP: 5.Psychosocial Impact of Alopecia Areata

EP: 6.Diagnosis of Alopecia Areata

EP: 7.Multimodal Care for Patients With Alopecia Areata

EP: 8.Deciding When to Treat Patients With Alopecia Areata

EP: 9.Choosing an Initial Therapy for Alopecia Areata

EP: 10.Adherence to Alopecia Areata Therapies

EP: 11.Adverse Events Associated With Conventional Alopecia Areata Therapies

EP: 12.Exploring Guidelines for Alopecia Areata

EP: 13.Unmet Needs for the Management of Alopecia Areata

EP: 14.Discussing Baricitinib for Alopecia Areata

EP: 15.Highlighting Deuruxolitinib for Alopecia Areata

EP: 16.Exploring Ritlecitinib for Alopecia Areata

EP: 17.Analyzing the Safety Data of JAK Inhibitors

EP: 18.SALT Scoring for Alopecia Areata

EP: 19.Rapid Therapeutic Effects Seen With a JAK Inhibitor

EP: 20.Future Treatment of Patients With Alopecia Areata

Now Viewing

EP: 21.Final Takeaways From the Panelists

Video content above is prompted by the following:

Thanks to all of you for this rich and informative discussion. Before we conclude I’d like to get final thoughts from each of you.